Polidocanol

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China

Retrieved on: 
Tuesday, May 30, 2023

This is CMS’s second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.

Key Points: 
  • This is CMS’s second innovative drug approved for marketing in China this year following the approval of Methotrexate Injection.
  • ILUMETRI is CMS’s second innovative drug approved to be marketed in China in 2023, following the recent approval of Methotrexate Injection.
  • ILUMETRI has been approved for marketing in the Hong Kong Special Administrative Region of China in April 2022.
  • Tildrakizumab Injection has also been approved for marketing in the U.S., EU, Japan, UK, Switzerland, Canada, Australia and other countries/regions.